We sought to review our experience in patients with severely impaired left ventricular function (ejection fraction (EF) ≤ 30%) who underwent minimally invasive mitral valve (MV) surgery (Mini-MV).
INTRODUCTION
Severe mitral valve (MV) dysfunction and secondary mitral regurgitation (MR) due to dilated or ischaemic ventricular disease lead to a deterioration of clinical status and is associated with a poor prognosis. The optimal management of this pathology is still debated and not yet clearly defined. Under optimal non-surgical therapy, the reported survival rates range from 50 to 87% at 1 year and decrease dramatically to <25% at 5 years [1] [2] [3] [4] [5] .
Newer interventional treatment strategies for secondary MR such as cardiac resynchronization therapy and percutaneous catheter-based MV interventions are of increasing interest, since they may lead to better quality of life and improved survival in congestive heart failure without major associated morbidity or mortality [6, 7] .
Cardiac surgical treatment including left ventricular assist device (LVAD) and heart transplantation is considered an end-stage option for selected patients, but of limited application due to costs and lack of long-term data for ventricular assist devices and donor organ shortage for heart transplantation. Traditional MV surgery is therefore the most common procedure performed in patients with secondary MR, and is a class IIB indication for highly symptomatic patients in the most recent valvular therapy guidelines [8] .
Because of the restrictive MV pathology observed in secondary MR, the preferred surgical strategy is to undersize the mitral annulus using a rigid annuloplasty ring with the goal of eliminating MR, symptomatic improvement and reverse left ventricular remodelling. The surgical philosophy of undersizing the mitral annulus to cure MR and secondarily to restore the shape of the LV from spherical to more ellipsoid geometry has been postulated and described by various authors [9] . However, the published surgical data are inconsistent, and the safety and effectiveness for this procedure have not been uniformly established [10, 11] .
Technical details and outcomes of MV surgery for secondary MR are of increasing interest and thoroughly debated in the cardiac surgery literature. In many specialized centres, minimally invasive mitral valve surgery (Mini-MV) has been become the preferred surgical approach to correct MV pathology, with equivalent safety and efficacy when compared with a median sternotomy approach [12] [13] [14] .
In this retrospective study, we sought to review our experience using Mini-MV procedures in patients with severe secondary MR with associated poor ventricular function. Clinical outcomes, patient demographics, operative characteristics and MV-related reintervention rates are reported and discussed, particularly with regard to conservative treatment strategies as estimated by the Seattle Heart Failure Model (SHFM).
PATIENTS AND METHODS

Study population, data collection and follow-up
We retrospectively examined all patients who presented with secondary MR and a left ventricular ejection fraction (EF) <30% undergoing Mini-MV between 1999 and 2010 at our institution. The primary indication for surgery was symptomatic severe MR in 172 patients (97.2%) and combined MR and mitral stenosis in 5 patients (2.8%). Clinical data including demographics, risk factors, history of previous cardiovascular surgery, symptoms, management details and postoperative mortality and morbidity were prospectively collected in our in-house database and retrospectively analysed. Details of preoperative patient characteristics are given in Table 1 . Concomitant tricuspid valve (TV) repair, atrial fibrillation ablation and closure of a patent foramen ovale/ atrial septal defect were performed as required (see Table 2 ).
Follow-up was obtained by telephone and/or mail interview with the patient and/or family member, as well as the family physician. The median follow-up time was 3.0 ± 2.5 years, and it was 94.0% complete. Institutional review board approval was granted for this analysis.
Operative technique
All surgical procedures were performed via our standard minimally invasive technique (i.e. right-lateral minithoracotomy and femoral cannulation for cardiopulmonary bypass (CPB) under transeosophageal guidance), which has been described elsewhere in detail [13, 14] .
In those patients requiring additional TV surgery or in patients weighing >75 kg, a second venous cannula was inserted percutaneously through the right internal jugular vein and advanced into the superior vena cava. Crystalloid cardioplegia (Brettschneider HTK, Germany) was administered antegrade directly into the ascending aorta. In patients with previous cardiac procedures, a CT-scan was performed preoperatively to assess the anatomy of surrounding structures. Some reoperative patients, in which exposure of the aorta was difficult due to adhesions, underwent MV surgery under moderate hypothermia (28°C) and a fibrillating heart.
We attempt to perform MV repair whenever possible in patients with secondary MR. Relative contraindications to MV repair were patients with an excessively dilated left ventricle (left ventricular internal diameter > 65 mm in diastole) or those with excessive leaflet tethering (>11 mm), or the presence of mitral stenosis. Our MV repair strategy for secondary MR is to perform a moderate undersized annuloplasty operation (one to two sizes less than the measured intertrigonal distance and the surface of the anterior leaflet), in order to minimize the risk of ring dehiscence. 
Statistical methods
Standard definitions were used for patient variables and outcomes. Categorical variables are expressed as percentages, and continuous variables are expressed as mean ± standard deviation (SD) throughout the manuscript. Actuarial survival was computed according to the Kaplan-Meier method and comparisons between treatment groups were performed with the log-rank test. The SHFM was used to generate a virtual survival curve using the baseline demographics and clinical parameters recorded prior to Mini-MV. This risk model can provide a standardized approach to estimate the risk in patients with heart failure, and provides a good correlation between predicted and observed survival (R 2 = 0.99) up to 5 years [15, 16] . In addition, we extrapolated the second 5-year course of the virtual survival curve in order to achieve a similar length of time as for the Mini-MV patients. Statistical analyses were performed using the SPSS 14.0 for Windows statistical software package (SPSS, Inc., Chicago, IL, USA) and the SHFM model online version of the University of Washington (http://depts. washington.edu/shfm/EULA.php). A P-value of <0.05 was considered to indicate statistical significance. Statistical support was supplied by the Department of Biostatistics of the University of Leipzig.
RESULTS
Surgical procedure and study population
Preoperative characteristics are summarized in Table 1 . Most patients had primary non-ischaemic dilated cardiomyopathy with severe secondary MR. A total of 32 patients had a previous cardiac procedure, mostly aortic valve replacement or coronary artery bypass surgery.
All patients underwent a Mini-MV procedure. The MV was repaired in 153 patients (86.4%) and replaced in the remaining 24 patients (13.6%). In 6 patients, an attempted MV repair resulted in excessive residual MR and a biological MV replacement was done during a second CPB run. No further MV re-repair was performed.
Five patients (2.9%) required a conversion to full median sternotomy due to severe bleeding in four patients and excessive adhesions in 1 patient. Concomitant procedures consisted of TV repair (n = 27; 15.4%), ablation therapy for atrial fibrillation (n = 48; 27.4%) and closure of an atrial septal defect (n = 10; 5.7%).
Regarding the MV pathology, annular dilatation with leaflet restriction was confirmed as the predominant pathology by intraoperative transoesophageal echocardiography in all patients. Additionally, a careful video-assisted direct analysis of the MV was performed by the surgeon and compared with the echocardiographic findings. These two techniques revealed a concomitant myxomatous component (i.e. mild chordal lengthening or fibroelastic deficiency) to the pathology in 44 patients (24.9%).
An MV down-sizing procedure using a complete annuloplasty ring (mean size 29 mm) was performed in 149 of the 153 MV repair operations (97.4%). A concomitant edge-to-edge repair was performed in 2 patients (1.1%).
The mean duration of CPB and aortic cross-clamp was 123 ± 64 and 67 ± 27 min, respectively. In 49 patients (28%), the Mini-MV was performed on a fibrillating heart (Table 3) .
Early mortality and outcome
No patient died intraoperatively. The overall 30-day mortality was 7.9% (14/177). Most patients required inotropic support postoperatively. Postoperative low cardiac output syndrome was observed in 15 patients (8.5%). Nine such patients were supported by an intra-aortic ballon pump (IABP) and 6 received extracorporeal membrane oxygenation (ECMO) for further stabilization. A total of 12 patients required surgical re-exploration within 24 h postoperatively because of excessive bleeding.
Sepsis was the main cause of in-hospital mortality. Cerebrovascular accidents, including transient or persistent neurological deficits, occurred in 4 patients (2.7%), 2 of which had undergone MV surgery during fibrillation. The majority of patients were treated for >24 h in the intensive care unit and the mean postoperative in-hospital stay was 17 ± 12 days (Table 4) .
Long-term outcome and reintervention
Long-term survival analysis using Kaplan-Meier estimates showed a survival of 78% (95% CI, 74-81%) at 1 year, 69% (95% CI, 61-76%) at 2 years, 53% (95% CI, 45-62%) at 5 years and 45.5% (95% CI, 35-56%) at 10 years ( Fig. 1 ). Concomitant procedures such as atrial fibrillation ablation or TV repair were associated with a non-significant trend towards improved survival.
Using the SHFM risk score, the predicted survival rate at 1, 2 and 5 years was 82.2, 70.3 and 41.2%, respectively (Fig. 1) . Survival rates of MV surgery patients and SHFM-predicted survival were not different for the first 2 years, but from the third year on the survival curves diverged with a significantly better survival for MV surgery patients. MV surgery was associated with an 12% higher survival after 5 years when compared with medical treatment. The survival rate at 10 years after Mini-MV was equal to the predicted medical treatment survival after 5 years, and approached the reported 10-year survival after heart transplantation [17] .
During the follow-up, 7 patients (4.0%) required reoperation because of progressive MR. Perioperative mortality in these 7 patients was 0%. The overall 10-year freedom from MV-related reoperation was 86.7% (95% CI, 80.5-91.1%) (Fig. 2) .
Thirteen patients required non-MV surgical therapy because of progressive deterioration in ventricular function. In 3 patients, an LVAD was inserted in the period of 4-8 months after initial Mini-MV procedure, and 10 patients underwent a heart transplantation 19 ± 23 months after Mini-MV. Two patients receiving LVAD support died and 1 patient was successfully transplanted. Within the 10-year period, 2 patients died after orthotopic heart transplantation (after 1 year and after 6 years).
DISCUSSION
Our observational single-centre study describes the long-term clinical experience and outcomes for Mini-MV procedures in patients with severe secondary MR and congestive heart failure.
This retrospective analysis included a total of 177 patients and therefore represents one of the largest series to date of Mini-MV procedures in patients with decreased left ventricular function (EF < 30%).
The main findings of this study are: (i) Mini-MV surgery can be carried out safely and effectively with an acceptable low 30-day mortality of 7.9% in patients with severely impaired left ventricular function and secondary MR; (ii) the observed longterm survival rates at 5 and 10 years are superior to the predicted survival rates for medical therapy using the risk score model SHFM; (iii) long-term survival 10 years postoperatively shows similar rates when compared with 10-year post-heart transplantation and (iv) Mini-MV repair leads to a low incidence of recurrent MR requiring reoperation. Our findings suggest that Mini-MV surgery is a feasible therapeutic option for patients with secondary MR and congestive heart failure, even in the presence of severe left ventricular dysfunction and older age.
It is known that cardiac surgery outcomes in patients with ischaemic cardiomyopathy, who tend to be older with more comorbidities, are inferior compared with younger patients with dilated cardiomyopathy. Of note is the superior outcome during the early postoperative course which is thought to justify a relatively high operative risk [18] . As we have seen in our own study population, the 30-day mortality is slightly higher despite most patients suffering from non-ischaemic cardiomyopathy [19] . This may be caused by two main factors: (i) the mean age of our study population is higher when compared with other studies; (ii) the combination of previous cardiac procedures, the proportion of ischaemic MR and the relatively high prevalence of comorbidities may have negatively impacted on perioperative mortality.
Controversy exists regarding optimal timing of surgery as well as regarding the overall benefit of surgery in patients with severe MR and low EF. Taking account of the fact that MV incompetence is associated with increasing mortality especially doubles the mortality in patients with functional MV insufficiency [5] . No randomized prospective study currently exists that compares MV surgery with conservative ( pharmacological) therapy. Therefore, risk-adjusted models like the SHFM may be of help to predict long-term mortality in medically managed patients, and may provide an estimate of the potential benefit of a surgical strategy.
In the current study, we observed a trend towards better survival for surgical patients when compared with the SHFM-based survival curve, particularly starting at 3 years post-surgery. The survival rate at 10 years after Mini-MV was equal to the predicted medical treatment survival after 5 years, and approached the reported 10-year survival after heart transplantation [17] . It should be stressed, however, that the SHFM survival prediction model does not allow prediction of 10-year outcomes.
We performed extrapolation of the predicted SHFM survival curve in order to achieve an estimate of 10-year survival for medically managed patients.
Our findings support an indication for MV surgery in this high-risk patient population. A possible survival benefit may be the result of reverse remodelling after the elimination of MR, due to reduced LV volume overload [8, 9] .
The long-standing question of whether an MV repair procedure is superior to prosthetic MV replacement in secondary MR is still an area of controversy. Although the benefits of MV repair in patients with degenerative MR are well documented and accepted [20] , such benefits are not proved in secondary MR patients. Spoor et al. [21] reported that the use of rigid rather than flexible annuloplasty rings is associated with a lower likelihood of recurrent MR requiring reoperation. However, some authors have argued against MV repair in high-risk secondary MR patients because of the relatively high rates of persistent or recurrent MR [22, 23] . In our series, we could not detect any significant influence of the type of annuloplasty ring used-i.e. rigid vs flexible ring-on valve reintervention rates. In addition, we failed to find an effect of underlying aetiology (i.e. ischaemic vs non-ischaemic) on early or late survival or recurrent MR, probably because of the limited number of patients with ischaemic MR.
The prognostic impact of concomitant procedure like atrial fibrillation ablation, TV reconstruction on relief of symptoms, recurrent MR and LV reverse remodelling have been postulated as another reason to consider surgery in patients with symptomatic secondary MR [24] . With our data, we found no significant negative effect on early outcomes and a trend towards improved long-term outcomes in patients undergoing these concomitant procedures. The presence of concomitant tricuspid regurgitation and atrial fibrillation may therefore be an important consideration for clinicians when deciding whether or not to refer secondary MR patients for surgery.
Our observed long-term survival of 45.5% 10 years postoperatively may seem to be suboptimal at first glance, but it is important to realize that this survival rate is similar to that achieved 10 years after heart transplantation [17] . Of course, heart transplantation is still the therapy of choice for patients with end-stage heart failure without medical contraindications, but MV surgery may represent a surgical option to improve heart failure symptoms and the natural course of heart failure, especially in the era of persistent organ shortages.
The shortage of appropriate donor hearts and the expanding pool of patients with congestive heart failure have led to growing interest in alternative strategies, particularly in mechanical circulatory support. With expanding clinical experience and continued technical advances, continuous-flow pumps are evolving from a bridge-to-transplantation strategy to destination therapy for advanced heart failure. To what extent ventricular assist device therapy can achieve good long-term results is still open to debate, but the increasing amount of good clinical results have led to a clear positive trend towards more implantations of these devices worldwide.
As far as alternative strategies in patients with secondary MR and advanced heart failure are concerned-e.g. cardiac resynchronization, percutaneous catheter-based techniques or ventricular reshaping devices-results are still somewhat preliminary and further data are required [6, 7, 19] . In addition, it is unlikely that a one-size-fits-all solution will be the reality in the future. However, we believe that a close interaction between cardiac surgeons and cardiologists using the Heart Team approach will be in best interests of these high-risk patients, in order to define the most appropriate, individualized therapy.
Study limitations
The main limitation of our study is its retrospective and observational nature and the subsequent treatment bias that is inherent in such studies. Patient selection and indication for surgery may also affect our findings because no formal heart failure team was involved to discuss alternative strategies-a situation which has been significantly altered in our current clinical practice.
Another limitation is the lack of echocardiographic follow-up. For our Mini-MV cohort, patients are referred from around the country and from international locations, making long-term echocardiographic follow-up difficult.
Another major limitation of our study is the lack of a control group. Although we tried to partially compensate for this shortcoming by using calculated survival rates from the SHFM risk score, this method is obviously inferior to a proper control group.
CONCLUSION
MV surgery using a minimally invasive approach is a relatively effective and safe treatment in low-EF patients with severe secondary MR. Such patients may receive a long-term survival benefit, when compared with predicted long-term survival from the SHFM risk score, but further data are required.
APPENDIX. CONFERENCE DISCUSSION
Dr E. Ferrari (Lausanne, Switzerland): For this specific study, you retrospectively analysed patients who underwent mitral valve surgery and selected a group of very high-risk patients with impaired left ventricular function, having an ejection fraction below 30%, operated on during a period of ten years. The results show a hospital mortality of 8% and a 10-year survival rate of 45%. Among these patients, 32 were redo patients, having had previous aortic valve procedures and CABG.
I have two comments and questions for you. First of all, I would like to explore why in 28% of these patients you have used ventricular fibrillation instead of using intra-aortic cross-clamping. I would be interested in your comments on that and whether you are using this technique instead of ventricular fibrillation in some cases. In your experience there were two patients with postoperative stroke.
Secondly, I think it is better to have learned something from this experience. We know that seven patients had progressive mitral regurgitation and were reoperated, and what comes out from your study is that they had a very bad outcome. So instead of trying to perform mitral valve reconstruction in such a very high-risk population of patients, why not go for direct replacement of the valve and try to reduce the risk of redo surgery?
Dr Garbade: Yes, in our cohort we do have a very high rate of redo procedures, and in this case, when there is no other option, we operate on a fibrillating heart, cool down to 28, with the patient in the Trendelburg position; that is our technique in Leipzig.
Of course we also use another technique, try to clamp if possible, particularly when you are able to transect the aorta and to use the Chitwood clamp in the correct place. Then, of course, it is a better way to operate on the mitral valve. But in this series, all patients after a previous surgery were operated on with a fibrillating heart.
As we have already heard in a previous talk, the endoclamp technique is also another tool. We also have experience with the endoclamp technique, but the experience that we had was not so convincing; we had a lot of complications with strokes and movements of the balloon catheter. That is why use of the endoclamp technique is no longer in our armamentarium. In some cases, yes, we use this device but usually not. The second question was regarding?
Dr Ferrari: Redo patients, and why not go straight for a mitral valve replacement in this kind of high-risk cohort of patients?
Dr Garbade: In the cohort of the 48 redos, we did 10 direct mitral valve replacements; in the other cases, the mitral valve was reconstructed successfully. Our intraoperative strategy is to leave the OR only when the mitral valve is functioning well. And that is why I have mentioned that in total we had conversions only in six patients. going from a failed mitral valve repair to direct replacement.
Dr M. Glauber (Massa, Italy): I have a question related to the decisionmaking. Patients with an ejection fraction less than 30 are really sick patients; there is a big difference when we evaluate patients with an EF less than 40 or 30; the mean ejection fraction in your population was 24. Concerning the echocardiographic criteria for performing a repair instead of replacement, it seems that there is still a gray zone area in which we do not know what is better for the long-term outcome. What is your view on that? And, secondly, I agree that ventricular fibrillation is an optimal way if you do not have aortic regurgitation more than mild.
Dr Garbade: With regard to the sick population, you are absolutely right that this cohort with a mean ejection fraction of 24 represents a very sick and very complex population. I presented the data from the last decade, and now we have a lot of newer presentations about MitraClip and other technology, or you can use CRT to improve mitral valve competence. In this cohort, of course, we had echo criteria to guide the decision or to estimate the success of a mitral valve repair. Of course, we measure the tenting height and coaptation depth, and the dimension of the left ventricle, but you are right -there is a gray zone. But in this series, our follow-up was not so effective and not so good that I could put these things in this presentation because our patient population comes from all of Germany, and sometimes it is very, very difficult to get an adequate follow-up to see how the LV is remodelled and so on.
Dr D. Mazzitelli (Munich, Germany): I would like to discuss your point that additional procedures like tricuspid repair should be done. If I understand correctly, you only have 15% of tricuspid repair in this group. In my experience, in heart failure patients presenting with severe mitral regurgitation, tricuspid repair is needed in more than 60% of cases. So my question is, might this low incidence of tricuspid repair be related to the access? What is the percentage of the group of 1,200 patients that you have done with sternotomy? What is the percentage of tricuspid repair in this group?
Dr Garbade: In this cohort, we only performed a minimally invasive approach. And you are absolutely right, in this cohort, 15% of the patients suffered from concomitant tricuspid valve insufficiency, and we fixed this problem. I have no data yet on comparison with a conventional sternotomy, and I have no explanation why only 15% within this cohort suffered from tricuspid valve dysfunction. So I cannot give a clear answer to that.
Dr M. Akay (Istanbul, Turkey): Fourteen years ago in the STS meeting, Dr Bolling presented mitral valve repair with the open technique in these heart failure patients with much better results in terms of operative mortality. If you treat these patients medically, the mortality rate is about 20-25% a year, and yours is really close to that. Preoperatively these patients are the heart transplant candidates. You do the surgery and they are still heart transplant candidates. How do you justify taking these patients to surgery? Dr Garbade: That is an extremely good question because it opens a completely new chapter. Because, of course, transplantation is the best therapy that we could offer, but the actual situation is the shortage of adequate donor organs everywhere. In this cohort, the mean age was 67. It is a relatively old patient population, and I think because of the lack of potential donor organs, this population is probably too sick to assign them for transplantation.
Dr S. Bolling (Ann Arbor, MI, USA): Obviously we have all learned quite a lot about how to take care of these patients, and we have become much better as surgeons in what to do with them. But the question from surgeons and also cardiologists remains what to do with these patients. This is a philosophical question only: Do you think the world is ready for a randomized prospective trial, either two-armed, what we do as surgeons against best medical therapy, or three-armed with a MitraClip percutaneous arm, a surgical arm, and medical therapy? Just a philosophical question.
Dr Glauber: I completely agree with Professor Bolling because I believe that the patients that we feel are too high-risk for surgery are the same patients who do not reach the anatomical criteria for a MitraClip. So I think that what we have to do and what we need is to make a bigger effort in collecting the data on these patients and even to analyse the echocardiographic data of such a big series as Leipzig.
